

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

|                        |                    |
|------------------------|--------------------|
| Application Number     | 09/787,461         |
| Filing Date            | March 2, 2001      |
| First Named Inventor   | Esteban Cvitkovich |
| Art Unit               | 1614               |
| Examiner Name          | Phyllis Spivack    |
| Attorney Docket Number | 13566.105002       |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|------------------------|--------------------------|---|----------------|
|                        |                          | Alexopoulos, "Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer," Ann. Oncol., 2004, 15(6):891-5  |                |
|                        |                          | D'Incalci et al., "Unique Features of the Mode of Action of ET-743", The Oncologist, 7, p. 210-216, June 2002   |                |
|                        |                          | Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, page 36, 1975  |                |
|                        |                          | Gourley C. et al., "Malignant mixed Mesodermal Tumours - Biology and Clinical Aspects," European Journal of Cancer 2002, vol. 38, no. 11, pages 1437-1446   |                |
|                        |                          | Halm et al., "A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma," Ann. Oncol., 2000, 11(1):113-114   |                |
|                        |                          | Hoekman et al., "A phase I/II study of dose-escalated docetaxel given two weekly in combination with a fixed dose of G-CSF," European Journal of Cancer, vol. 37, page S76, Abstract 270, October 22, 2001  |                |
|                        |                          | Horstmann et al., "Risks and Benefits of Phase I Oncology Trials, 1991 through 2002," New England Journal of Medicine, vol. 352, pages 895-904; March 3, 2005   |                |
|                        |                          | Puchalski et al., "Pharmacokinetics of Ecteinascidin 743 Administered as a 24-h Continuous Intravenous Infusion to Adult Patients with Soft Tissue Sarcomas associations with Clinical Characteristics, Pathophysiological Variables and Toxicity," Cancer Chemotherapy and Pharmacology, 2002, vol. 50, no. 4, pages 309-319 |                |
|                        |                          | Rote Liste 2002 "Doxorubicin," entries 86-056 through 86-062, 2002  |                |
|                        |                          | Schwartzmann G. et al., "Marine Organisms as a Source of New Anticancer Agents," The Lancet Oncology, 2001, vol. 2, no. 4, pages 221-225  |                |
|                        |                          | Twelves et al., "Phase I and pharmacokinetic study of Yondelis <sup>TM</sup> (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours," European Journal of Cancer, vol. 39, p. 1842-1851, 2003; available online August 14, 2003                                 |                |
|                        |                          | Wollina, "Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma," Cancer 2003, 1:98(5):993-1001, published online July 24, 2003   |                |
|                        |                          | Wright et al., "Antitumor Tetrahydroisoquinoline Alkaloids from the Colonial Ascidian Ecteinascidia Turbinata", J. Org. Chem., vol. 55, pp. 4508-4512, 1990   |                |

Examiner  
Signature

/James Anderson/

Date  
Considered

01/08/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary.

978097

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/